OverviewSuggest Edit

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate, or ADC, platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. It engineers immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because the Company can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

TypePublic
Founded2005
HQCambridge, US
Websitemersana.com
Employee Ratings4.8

Latest Updates

Employees (est.) (Jan 2019)86(+11%)
Revenue (FY, 2016)$25.2 M(+143%)
Share Price (Oct 2019)$1.5 (-6%)

Key People/Management at Mersana Therapeutics

Donald A. Bergstrom

Donald A. Bergstrom

Chief Medical Officer
Timothy B. Lowinger

Timothy B. Lowinger

Chief Scientific Officer
Karen Hong

Karen Hong

Principal, ProQuest Investments
Eva Jack

Eva Jack

Chief Business Officer
Wayne Foster

Wayne Foster

Vice President of Finance
Michael A. Metzger

Michael A. Metzger

Executive Vice President and Chief Operating Officer
Show more

Mersana Therapeutics Office Locations

Mersana Therapeutics has an office in Cambridge
Cambridge, US (HQ)
840 Memorial Dr
Show all (1)

Mersana Therapeutics Financials and Metrics

Mersana Therapeutics Revenue

Mersana Therapeutics's revenue was reported to be $25.17 m in FY, 2016 which is a 143% increase from the previous period.
USD

Revenue (FY, 2016)

25.2m

Revenue growth (FY, 2015 - FY, 2016), %

143%

Net income (FY, 2016)

(13.7m)

Market capitalization (11-Oct-2019)

71.7m

Closing stock price (11-Oct-2019)

1.5

Cash (31-Dec-2016)

100.3m
Mersana Therapeutics's current market capitalization is $71.7 m.
USDFY, 2015FY, 2016

Revenue

10.4m25.2m

Revenue growth, %

143%

General and administrative expense

5.3m7.0m

R&D expense

21.4m32.0m
USDFY, 2015FY, 2016

Cash

11.5m100.3m

Accounts Receivable

640.0k1.1m

Current Assets

12.8m102.2m

PP&E

1.3m2.5m
USDFY, 2015FY, 2016

Net Income

(16.4m)(13.7m)

Depreciation and Amortization

297.0k655.0k

Accounts Payable

926.0k(325.0k)

Cash From Operating Activities

(9.6m)31.6m
USDY, 2016

Financial Leverage

-1.9 x
Show all financial metrics

Mersana Therapeutics Operating Metrics

Apr, 2017

Patents (US)

7

Patents Pending (US)

10
Show all operating metrics

Mersana Therapeutics Online and Social Media Presence

Embed Graph

Mersana Therapeutics News and Updates

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates

CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it…

Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019

Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond

Company to Focus its Resources on Advancing XMT-1536, its First-in-Class ADC Candidate Targeting NaPi2b, Showing Encouraging Early Signs of Efficacy

Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates

XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019

Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer

CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced it …

Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced tha…
Show more

Mersana Therapeutics Blogs

Mersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and Non-Small Cell Lung Cancer

CAMBRIDGE, Mass. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the

Mersana Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Updates

Patient Dosing in XMT-1536 Phase 1 Expansion Study Expected to Commence in Third Quarter 2019 Ended Second Quarter 2019 with $128 Million in Cash CAMBRIDGE, Mass. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2019 Financial Results and Business Updates

CAMBRIDGE, Mass. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. , (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy

Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass. , June 12, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company

Mersana Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference

CAMBRIDGE, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass. , May 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it
Show more

Mersana Therapeutics Frequently Asked Questions

  • When was Mersana Therapeutics founded?

    Mersana Therapeutics was founded in 2005.

  • Who are Mersana Therapeutics key executives?

    Mersana Therapeutics's key executives are Donald A. Bergstrom, Timothy B. Lowinger and Karen Hong.

  • How many employees does Mersana Therapeutics have?

    Mersana Therapeutics has 86 employees.

  • What is Mersana Therapeutics revenue?

    Latest Mersana Therapeutics annual revenue is $25.2 m.

  • What is Mersana Therapeutics revenue per employee?

    Latest Mersana Therapeutics revenue per employee is $292.7 k.

  • Who are Mersana Therapeutics competitors?

    Competitors of Mersana Therapeutics include Araris Biotech, MyoKardia and Athersys.

  • Where is Mersana Therapeutics headquarters?

    Mersana Therapeutics headquarters is located at 840 Memorial Dr, Cambridge.

  • Where are Mersana Therapeutics offices?

    Mersana Therapeutics has an office in Cambridge.

  • How many offices does Mersana Therapeutics have?

    Mersana Therapeutics has 1 office.